Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy

xlomafota13 shared this article with you from Inoreader Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct 29:S0007-4551(21)00392-1. doi: 10.1016/j.bulcan.2021.08.010. Online ahead of print. NO ABSTRACT PMID:34756719 | DOI:10.1016/j.bulcan.2021.08.010 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.